| 1 |
31714586 | Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. | 2020 Jul 15 |
2 |
| 2 |
31277699 | Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. | 2019 Jul 5 |
3 |
| 3 |
28874413 | A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. | 2017 Nov 15 |
4 |
| 4 |
26742424 | Phosphatidylinositol 3-kinase p110α mediates phosphorylation of AMP-activated protein kinase in myoblasts. | 2016 Jan 22 |
2 |
| 5 |
25349966 | Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. | 2014 Nov 25 |
1 |
| 6 |
23888070 | PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. | 2013 Oct 1 |
1 |
| 7 |
22932669 | Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. | 2012 Oct 15 |
4 |